Rai P, Ataga K
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):519-531.
PMID: 38066905
PMC: 10727073.
DOI: 10.1182/hematology.2023000485.
Ataga K
Blood. 2023; 142(24):2047-2054.
PMID: 37890140
PMC: 10733825.
DOI: 10.1182/blood.2023021220.
Conran N, Embury S
Exp Biol Med (Maywood). 2021; 246(12):1458-1472.
PMID: 33794696
PMC: 8243211.
DOI: 10.1177/15353702211005392.
Rai P, Ataga K
F1000Res. 2020; 9.
PMID: 32765834
PMC: 7388199.
DOI: 10.12688/f1000research.22433.1.
Nasimuzzaman M, Malik P
Blood Adv. 2019; 3(20):3170-3180.
PMID: 31648337
PMC: 6849940.
DOI: 10.1182/bloodadvances.2019000193.
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.
Amilon C, Niazi M, Berggren A, Astrand M, Hamren B
Clin Pharmacokinet. 2019; 58(10):1295-1307.
PMID: 30972696
DOI: 10.1007/s40262-019-00758-0.
Advances in new drug therapies for the management of sickle cell disease.
Ataga K, Desai P
Expert Opin Orphan Drugs. 2019; 6(5):329-343.
PMID: 30873300
PMC: 6411095.
DOI: 10.1080/21678707.2018.1471983.
New Therapeutic Options for the Treatment of Sickle Cell Disease.
Matte A, Zorzi F, Mazzi F, Federti E, Olivieri O, De Franceschi L
Mediterr J Hematol Infect Dis. 2019; 11(1):e2019002.
PMID: 30671208
PMC: 6328043.
DOI: 10.4084/MJHID.2019.002.
Therapeutic strategies for sickle cell disease: towards a multi-agent approach.
Telen M, Malik P, Vercellotti G
Nat Rev Drug Discov. 2018; 18(2):139-158.
PMID: 30514970
PMC: 6645400.
DOI: 10.1038/s41573-018-0003-2.
Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study.
Kanter J, Abboud M, Kaya B, Nduba V, Amilon C, Gottfridsson C
Br J Haematol. 2018; 184(2):269-278.
PMID: 30443999
PMC: 6587797.
DOI: 10.1111/bjh.15646.
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S, Ballas S
Cochrane Database Syst Rev. 2018; 10():CD003426.
PMID: 30338520
PMC: 6517013.
DOI: 10.1002/14651858.CD003426.pub6.
A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study.
Hsu L, Sarnaik S, Williams S, Amilon C, Wissmar J, Berggren A
Am J Hematol. 2018; 93(12):1493-1500.
PMID: 30187935
PMC: 6282821.
DOI: 10.1002/ajh.25273.
Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.
Sins J, Mager D, Davis S, Biemond B, Fijnvandraat K
Blood Adv. 2018; 1(19):1598-1616.
PMID: 29296801
PMC: 5728463.
DOI: 10.1182/bloodadvances.2017007211.
Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.
Noubouossie D, Key N, Ataga K
Blood Rev. 2016; 30(4):245-56.
PMID: 26776344
PMC: 4919240.
DOI: 10.1016/j.blre.2015.12.003.
Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.
Arumugam P, Mullins E, Shanmukhappa S, Monia B, Loberg A, Shaw M
Blood. 2015; 126(15):1844-55.
PMID: 26286849
PMC: 4600020.
DOI: 10.1182/blood-2015-01-625707.
Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.
Pakbaz Z, Wun T
Hematol Oncol Clin North Am. 2014; 28(2):355-74.
PMID: 24589271
PMC: 3984936.
DOI: 10.1016/j.hoc.2013.11.011.
A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.
Desai P, Brittain J, Jones S, McDonald A, Wilson D, Dominik R
Thromb Res. 2013; 132(3):341-5.
PMID: 23973010
PMC: 3791139.
DOI: 10.1016/j.thromres.2013.08.002.
Interplay between coagulation and vascular inflammation in sickle cell disease.
Sparkenbaugh E, Pawlinski R
Br J Haematol. 2013; 162(1):3-14.
PMID: 23593937
PMC: 3878906.
DOI: 10.1111/bjh.12336.
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Wun T, Soulieres D, Frelinger A, Krishnamurti L, Novelli E, Kutlar A
J Hematol Oncol. 2013; 6:17.
PMID: 23414938
PMC: 3585853.
DOI: 10.1186/1756-8722-6-17.
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Jakubowski J, Zhou C, Small D, Winters K, Lachno D, Frelinger 3rd A
Br J Clin Pharmacol. 2012; 75(6):1433-44.
PMID: 23171128
PMC: 3690102.
DOI: 10.1111/bcp.12042.
